SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                                   __________

                                    FORM 8-K
                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                       DATE OF REPORT:  FEBRUARY 13, 2001
                        (Date of earliest event reported)

                              INCYTE GENOMICS, INC.
             (Exact name of registrant as specified in its charter)

              DELAWARE                    0-27488      94-3136539
         (State or other jurisdiction (Commission     (IRS Employer
           of incorporation)          File Number)  Identification No.)

             3160 PORTER DRIVE, PALO ALTO, CALIFORNIA 94304
            (Address of principal executive offices) (Zip Code)


       Registrant's telephone number, including area code:  (650) 855-0555


Item  5.          Other  Events.
                  -------------
     Attached  hereto  as  Exhibit  99.1 and incorporated by reference herein is
financial  information  for Incyte Genomics, Inc. for the quarter and year ended
December  31,  2000.

Item  7.          Financial  Statements  and  Exhibits.
                  ------------------------------------
(a)     Exhibits.
99.1     Incyte  Genomics, Inc. Financial Results for the Quarter and Year Ended
December  31,  2000.



                                    SIGNATURE
     Pursuant  to  the  requirements of the Securities Exchange Act of 1934, the
registrant  has  duly  caused  this  report  to  be  signed on its behalf by the
undersigned  hereunto  duly  authorized.

Dated:  February  13,  2001.

INCYTE  GENOMICS,  INC.



By     /s/  John  M.  Vuko
       -------------------
       John M. Vuko
       Executive Vice President and
       Chief Financial Officer


                                INDEX TO EXHIBITS





             
          
Exhibit Number  Description
--------------
99.1 . . . . .  Incyte Genomics, Inc. Financial Results for the Quarter and
                Year Ended December 31, 2000.